The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity

Prior treatment

• Any antidiabetic medication (insulin, metformin, GLP-1RA, SGLT2i, etc.), or anti-obesity pharmacotherapy.
• Participation in another interventional study within the previous 3 months.

Other illness

• Endocrine disorders affecting metabolism (e.g., untreated thyroid disease, Cushing's syndrome).
• Severe psychiatric illness or cognitive impairment limiting adherence or comprehension.
• Known allergy or skin reaction to CGM adhesives or device materials.

Lab values

• Diagnosis of type 1 or type 2 diabetes mellitus (fasting glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5%).
• Severe chronic disease that could influence glucose metabolism or study participation (e.g., chronic liver disease, renal failure, active malignancy).
• Use of medications known to affect glucose metabolism (e.g., corticosteroids, atypical antipsychotics).

Other

• Current or recent (within 3 months) use of:
• Pregnancy, breastfeeding, or planned pregnancy during the study period.
• Implanted electronic medical devices (e.g., pacemaker, defibrillator) that may interfere with CGM function.

• Adults aged 18-70 years.
• BMI ≥ 27 kg/m² (overweight or obese).
• Prediabetes, confirmed by:
  • Impaired fasting glucose (IFG: 5.6-6.9 mmol/L), and/or Impaired glucose tolerance (IGT: 2-hour OGTT glucose 7.8-11.0 mmol/L).
• Stable body weight (±3 kg) in the last 3 months.
• No current use of antidiabetic or weight-loss medications.
• Willingness and ability to wear a CGM device as instructed.
• Capacity to provide written informed consent.
• Recruitment from the Diabetes Outpatient Clinic, Community Health Center Koper (identified and invited from the clinic's database).